FDA Preliminary Review Finds No Suicidal Risk for Lilly’s GLP-1 Therapies
The FDA’s preliminary review of adverse event and clinical-trial data for GLP-1 receptor agonists, including Eli Lilly’s obesity and diabetes therapies, identified no link to suicidal thoughts or actions. The agency has launched a meta-analysis across all GLP-1 RA trials and postmarketing Sentinel reviews to conclude on safety.
1. Eli Lilly Shares Surge 41% After Ventyx Acquisition Eases Competitor Concerns
Between August and December 2025, Eli Lilly shares climbed 41% as investors responded positively to the company’s $6 billion acquisition of Ventyx Biosciences. Analysts noted that the deal expands Lilly’s metabolic franchise beyond its blockbuster GLP-1 therapy, diversifying revenue streams and reducing perceived dependence on weight-loss drugs facing competitive pressure. The transaction also adds two phase III candidates targeting nonalcoholic steatohepatitis and type 2 diabetes, boosting Lilly’s late-stage pipeline to 14 programs. Institutional buyers increased net inflows by 28% in the fourth quarter, signaling renewed confidence in long-term growth prospects.
2. Nvidia Partnership Marks $1 Billion AI Investment to Accelerate Drug Discovery
At the 2026 JPMorgan Healthcare Conference, Eli Lilly announced a five-year co-innovation lab with Nvidia, backed by a joint $1 billion commitment. The collaboration will deploy Nvidia’s DGX SuperPOD supercomputer infrastructure and Vera Rubin AI chips to train advanced machine-learning models on Lilly’s proprietary compound libraries. Objectives include reducing candidate identification timelines by up to 70% and cutting preclinical costs by 30–40%. The lab will be staffed by a multidisciplinary team of 50 data scientists and chemists in the San Francisco Bay Area, positioning Lilly at the forefront of AI-driven R&D and potentially unlocking $60–110 billion in annual pharma value by 2030.
3. FDA Safety Update Supports Continued Use of GLP-1 Therapies
In a preliminary safety review issued by the U.S. Food and Drug Administration, no clear link was found between GLP-1 receptor agonist therapies and suicidal thoughts or actions. The agency examined adverse-event reports and clinical-trial data across multiple manufacturers, including Lilly’s metabolic portfolio, finding low incidence rates in both treatment and control arms. Although the FDA will conduct a meta-analysis of all GLP-1 trials and mine its Sentinel database, it reiterated existing label warnings and advised patients to consult physicians before discontinuing therapy. Eli Lilly’s Chief Medical Officer highlighted that these findings should reassure prescribers and support ongoing uptake of its obesity and diabetes treatments.